Adjuvant durvalumab therapy improves survival in limited-stage …
Nov 21, 2024 · 1. In this randomized controlled trial, adjuvant therapy with durvalumab led to improved overall and progression-free survival compared to placebo in patients with limited …
GPT-4 performing with superior scores on medical oncology …
Dec 17, 2024 · 1. The large language model, ChatGPT-4, answered 85.0% of examination-style multiple-choice questions on medical oncology correctly, a performance superior to all other …
Landmark Trials & Summaries: The Classics in Medicine - 2 Minute …
Title Year Journal Citations Key findings; The UKPDS: Reducing the risk of diabetes-related morbidity and mortality: 1998: Lancet: 20,000: 1. For patients with type 2 diabetes mellitus, …
Invasive treatment not superior to medical therapy in older adults …
Dec 10, 2024 · 1. In this randomized controlled trial, in older adults with non-ST-segment elevation myocardial infarction (NSTEMI), invasive treatment did not significantly reduce the …
Tulisokibart effectively induces clinical remission in moderately to ...
Oct 3, 2024 · 1. In this randomized controlled trial, among patients with moderately to severely active ulcerative colitis, tulisokibart, a monoclonal antibody directed against TL1A, more …
Ponsegromab for the Treatment of Cancer Cachexia
Sep 23, 2024 · 1. Ponsegromab at increasing doses resulted in a mean increase in body weight compared to placebo; 1.22 kg (2.21%) in the 100-mg group, 1.92 kg (2.99%) in the 200-mg …
Beta-blocker interruption not noninferior to continuation following ...
Nov 21, 2024 · 1. In this randomized controlled trial, among patients with a history of myocardial infarction (MI), interruption of long-term beta-blocker therapy was not found to be noninferior to …
Home | 2 Minute Medicine
2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and …
Imlunestrant with or without Abemaciclib in Advanced Breast Cancer
Dec 16, 2024 · 1. Median progression-free survival was 9.4 months in the imlunestrant–abemaciclib group vs 5.5 months in the imlunestrant group with HR 0.57 …
Glucagon-like peptide-1 receptor agonists may impact outcomes …
Oct 28, 2024 · 1. The use of glucagon-like peptide 1 (GLP-1) receptor agonists in adults with type 2 diabetes mellitus (T2DM) was not associated with increased risks of pulmonary aspiration …